Transcription factor Maf also known as proto-oncogene c-Maf or V-maf musculoaponeurotic fibrosarcoma oncogene homolog is a transcription factor that in humans is encoded by the MAFgene.[1][2]
↑ 5.05.1Chen Q, Dowhan DH, Liang D, Moore DD, Overbeek PA (Jul 2002). "CREB-binding protein/p300 co-activation of crystallin gene expression". The Journal of Biological Chemistry. 277 (27): 24081–9. doi:10.1074/jbc.M201821200. PMID11943779.
↑Huang W, Lu N, Eberspaecher H, De Crombrugghe B (Dec 2002). "A new long form of c-Maf cooperates with Sox9 to activate the type II collagen gene". The Journal of Biological Chemistry. 277 (52): 50668–75. doi:10.1074/jbc.M206544200. PMID12381733.
Further reading
Kerppola TK, Curran T (Mar 1994). "Maf and Nrl can bind to AP-1 sites and form heterodimers with Fos and Jun". Oncogene. 9 (3): 675–84. PMID8108109.
Kurschner C, Morgan JI (Feb 1997). "USF2/FIP associates with the b-Zip transcription factor, c-Maf, via its bHLH domain and inhibits c-Maf DNA binding activity". Biochemical and Biophysical Research Communications. 231 (2): 333–9. doi:10.1006/bbrc.1997.6097. PMID9070273.
Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T, Schröck E, Ried T, Kuehl WM (Jun 1998). "Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma". Blood. 91 (12): 4457–63. PMID9616139.
Christodoulopoulos P, Cameron L, Nakamura Y, Lemière C, Muro S, Dugas M, Boulet LP, Laviolette M, Olivenstein R, Hamid Q (Apr 2001). "TH2 cytokine-associated transcription factors in atopic and nonatopic asthma: evidence for differential signal transducer and activator of transcription 6 expression". The Journal of Allergy and Clinical Immunology. 107 (4): 586–91. doi:10.1067/mai.2001.114883. PMID11295643.
Jamieson RV, Perveen R, Kerr B, Carette M, Yardley J, Heon E, Wirth MG, van Heyningen V, Donnai D, Munier F, Black GC (Jan 2002). "Domain disruption and mutation of the bZIP transcription factor, MAF, associated with cataract, ocular anterior segment dysgenesis and coloboma". Human Molecular Genetics. 11 (1): 33–42. doi:10.1093/hmg/11.1.33. PMID11772997.
Chen Q, Dowhan DH, Liang D, Moore DD, Overbeek PA (Jul 2002). "CREB-binding protein/p300 co-activation of crystallin gene expression". The Journal of Biological Chemistry. 277 (27): 24081–9. doi:10.1074/jbc.M201821200. PMID11943779.
Cousins DJ, Lee TH, Staynov DZ (Sep 2002). "Cytokine coexpression during human Th1/Th2 cell differentiation: direct evidence for coordinated expression of Th2 cytokines". Journal of Immunology. 169 (5): 2498–506. doi:10.4049/jimmunol.169.5.2498. PMID12193719.
Huang W, Lu N, Eberspaecher H, De Crombrugghe B (Dec 2002). "A new long form of c-Maf cooperates with Sox9 to activate the type II collagen gene". The Journal of Biological Chemistry. 277 (52): 50668–75. doi:10.1074/jbc.M206544200. PMID12381733.
Valanciuté A, le Gouvello S, Solhonne B, Pawlak A, Grimbert P, Lyonnet L, Hue S, Lang P, Remy P, Salomon R, Bensman A, Guellaën G, Sahali D (Jan 2004). "NF-kappa B p65 antagonizes IL-4 induction by c-maf in minimal change nephrotic syndrome". Journal of Immunology. 172 (1): 688–98. doi:10.4049/jimmunol.172.1.688. PMID14688382.
Rasmussen T, Knudsen LM, Dahl IM, Johnsen HE (Oct 2003). "C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance". Leukemia & Lymphoma. 44 (10): 1761–6. doi:10.1080/1042819031000111035. PMID14692531.
Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM, Staudt LM (Feb 2004). "Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma". Cancer Cell. 5 (2): 191–9. doi:10.1016/S1535-6108(04)00019-4. PMID14998494.
Morito N, Yoh K, Fujioka Y, Nakano T, Shimohata H, Hashimoto Y, Yamada A, Maeda A, Matsuno F, Hata H, Suzuki A, Imagawa S, Mitsuya H, Esumi H, Koyama A, Yamamoto M, Mori N, Takahashi S (Jan 2006). "Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human". Cancer Research. 66 (2): 812–9. doi:10.1158/0008-5472.CAN-05-2154. PMID16424013.
Vanita V, Singh D, Robinson PN, Sperling K, Singh JR (Mar 2006). "A novel mutation in the DNA-binding domain of MAF at 16q23.1 associated with autosomal dominant "cerulean cataract" in an Indian family". American Journal of Medical Genetics Part A. 140 (6): 558–66. doi:10.1002/ajmg.a.31126. PMID16470690.